The shingles (herpes zoster) and post-herpetic neuralgia preventive drug Shingrix (Zoster Vaccine Recombinant, Adjuvanted) has been made available in India by the British company GlaxoSmithKline (GSK) Pharmaceuticals for individuals 50 years of age and older.
The first non-live, recombinant subunit vaccination given intramuscularly in two doses is called Shingrix. The varicella zoster virus (VZV), which also causes chickenpox, stimulates and causes shingles.
By the age of 40, more than 90% of Indian subjects in a seroprevalence research had this virus in their bodies and were at risk for developing shingles. A painful rash results from shingles. In every case, the rash goes away, but the agony frequently lasts for months or years. The medical term for this discomfort is post-herpetic neuralgia (PHN).
Shingrix is now permitted by the US Food and Drug Administration (FDA) for the treatment of shingles risk for those 50 years of age or older.The European Commission accorded its consent.Shingrix for use in people 50 years of age or older to prevent shingles.